Key takeaways:
Mounjaro and Zepbound are once-weekly injections that contain the same active ingredient: tirzepatide. Mounajro is FDA-approved to treat Type 2 diabetes, and Zepbound is FD- approved for weight management.
Constipation is a common side effect of taking tirzepatide. But it’s not as common as other digestive side effects like nausea, stomach pain, and diarrhea.
Drinking water and eating more fiber can help relieve Mounjaro-related constipation.
Tirzepatide is a weekly injectable prescription medication that’s approved by the FDA to treat Type 2 diabetes under the brand name Mounjaro. Tirzepatide is also FDA-approved for chronic weight management under the brand name Zepbound.
People who take Mounjaro can experience side effects, such as constipation. But there are ways to help prevent constipation when taking Mounjaro. Here’s everything you need to know to manage Mounjaro-related constipation.
Yes, Mounjaro can cause constipation.
Save every month on GLP-1 meds with GoodRx
Save an average of $235 on FDA-approved GLP-1s like Ozempic and Zepbound.
In clinical trials, constipation was a commonly reported side effect among people taking Mounjaro. About 6% to 7% of people in the clinical studies experienced constipation while taking Mounjaro. More recent studies also suggest that people taking Mounjaro are more likely to experience constipation than people taking glucagon-like peptide-1 (GLP-1) agonists, like Ozempic (semaglutide).
But there’s some good news. First, in clinical trials, people taking higher doses weren’t more likely to have constipation. So, taking a higher dose doesn’t mean you’re more likely to develop constipation.
Second, people don’t experience constipation as often as they do other digestive problems like nausea, stomach upset, and diarrhea. And, in clinical trials, only a small number of people who developed side effects decided to stop taking Mounjaro. This is a sign that the benefits of sticking with the medication outweigh the negatives of side effects.
It’s not clear why tirzepatide causes gut-related side effects. But it likely has to do with how tirzepatide affects the gut.
Tirzepatide slows down how fast the stomach empties. This helps people feel fuller longer so they eat less throughout the day. But this also means they’re more likely to drink less fluid throughout the day. Also, tirzepatide tells your body to release more insulin. Insulin can slow down how fast the gut moves, too. The combination of a slow-moving gut and less fluid intake leads to constipation.
A slower-moving gut means you poop less often. The stool in your gut sits around longer, becoming harder and more difficult to pass. Also, if you’re drinking less water, your stool becomes dry and even harder.
Less fiber intake is another reason people might develop constipation while taking Mounjaro. Fiber bulks stool and makes it easier to pass. But fiber intake can also worsen other Mounjaro-related side effects like nausea, gassiness, and bloating. People may naturally avoid fiber-rich foods while taking Mounjaro, which further worsens their constipation.
It’s not clear. There are no studies looking at how long constipation lasts after starting Mounjaro. But in general, side effects from GLP-1 agonists get better over time. It’s likely that Mounjaro-related constipation follows the same pattern. As your body gets used to the medication, your stooling patterns will start to return to normal. It’s just not clear how long this will take.
Other GLP-1 agonists may offer some clues. Ozempic is a GLP-1 agonist and also causes constipation. Studies suggest that Ozempic-related constipation lasts about 6 weeks. It’s possible that Mounjaro-related constipation may also take several weeks to resolve.
There are things you can do to manage constipation from Mounjaro:
Drink more water. You’re less likely to drink enough fluids while taking Mounjaro. Set yourself a daily water goal and use a water bottle to help keep track of how much you drink. Most people need between 2.7 L and 3.7 L of water each day.
Move more. Physical activity gets all the muscles in your body moving, including the ones around your intestines. Adding a walk or exercise to your daily routine can help treat your constipation and helps Mounjaro work better, too.
Focus on fiber. You can add more fiber to your diet by eating high-fiber foods like fruits, vegetables, and whole grains. You can also try a fiber supplement, like Metamucil. Make sure to slowly add fiber into your daily routine. But keep in mind that taking too much fiber too fast can worsen other Mounjaro side effects like gassiness and bloating.
Change your toilet habits. Getting back to basics can help you with constipation. Make the most of your gastrocolic reflex by trying to stool about 30 minutes after a meal. You can also use a toilet stool to raise your feet (like a Squatty Potty). This can make it easier to have a bowel movement. And if at any point during the day you get the urge to go, don’t put it off. Use your body’s natural reflexes to get your stooling patterns back on track.
Try a laxative. There are many types of over-the-counter (OTC) laxatives that can make it easier to have a bowel movement. Each type of laxative works differently. Your healthcare professional may have suggestions about which laxatives work best for Mounjaro-related constipation.
Talk with your healthcare professional if these tips don’t offer you relief. They may have additional tips and suggestions to help ease your constipation so you can keep taking Mounjaro.
Mounjaro is a weekly injection medication that can help treat adults with Type 2 diabetes. Constipation is a side effect of Mounjaro. About 6% to 7% of people experienced constipation while taking Mounjaro. Fluids, fiber, and laxatives can help ease Mounjaro-related constipation.
Eli Lilly and Company. (2022). Mounjarot (tirzepatide) injection, for subcutaneous use [package insert].
Eli Lilly and Company. (2023). Mounjaro- tirzepatide injection, solution [package insert].
Karrar, H. R., et al. (2023). Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis. Cureus.
Malone, J. C., et al. (2023). Physiology, gastrocolic reflex. StatPearls.
Marathe, C. S., et al. (2011). Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Experimental Diabetes Research.
Wharton, S., et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity & Metabolism.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.